Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia
While the bivalent Moderna vaccine induced higher immune responses than the Ancestral Novavax vaccine as a fourth dose, both vaccines appeared to provide comparable protection against SARS-CoV-2 Omicron variants over 12-months.
Authors
- K. Subbarao
- Paul V. Licciardi (ORCID: https://orcid.org/0000-0001-6086-6285)
- Rachel A. Higgins
- Cattram Nguyen (ORCID: https://orcid.org/0000-0002-0599-8645)
- Nadia Mazarakis (ORCID: https://orcid.org/0000-0001-7681-2775)
- John Hart (ORCID: https://orcid.org/0000-0002-9637-7974)
- Kerryn A. Moore (ORCID: https://orcid.org/0000-0002-8333-8271)
- Darren Suryawijaya Ong (ORCID: https://orcid.org/0000-0001-6409-1376)
- Claire von Mollendorf (ORCID: https://orcid.org/0000-0003-0927-1731)
- Fran Justice
- Eleanor Neal (ORCID: https://orcid.org/0000-0001-7998-0942)
- Kathryn Bright
- Zheng Quan Toh (ORCID: https://orcid.org/0000-0002-0282-5837)
- Leanne Quah
- Yan Yung Ng
- Lien Anh Ha Do
- Skyy Luu
- Shashini Dassanayake
- Anna Rudel
- Emma Watts
- Rachael Carissa
- Kim Mulholland
Institutions
- Peter Doherty Institute (AU)
- Murdoch Children's Research Institute (AU)
Publication Details
- Journal
- Journal of Infection
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1016/j.jinf.2026.106727
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Children’s Hospital of Wisconsin Research Institute
- Murdoch Children's Research Institute
- Coalition for Epidemic Preparedness Innovations